Introduction
Hepatitis B virus (HBV) infection is considered as one of the most important global public health concerns; this potentially life-threatening infection damages the liver and can contribute to acute and chronic diseases. An estimated 240 million individuals are chronically infected with HBV worldwide, and over 686,000 individuals die annually because of end-stage chronic hepatitis B (CHB) and CHB-associated complications such as decompensated cirrhosis and hepatocellular carcinoma. 1 of both these drugs were demonstrated through previous clinical trials. 3 Safety should be particularly considered, since long-term treatment for CHB is usually required with ETV or TDF, although its ideal duration of treatment is not well determined. 5 ETV and TDF may cause renal toxicity via various mechanisms such as renal tubular injury, apoptosis, and mitochondrial toxicity. 5, 6 Previous studies also reported an association between CHB and chronic kidney disease (CKD). [7] [8] [9] [10] [11] Specifically, it was reported that glomerular diseases, such as membranous nephropathy and mesangiocapillary glomerulonephritis, might be the underlying causes of renal dysfunction in patients with CHB. 12, 13 Moreover, drug history except for NUCs, disease status of diabetes and/or hypertension (HTN), and baseline (BL) kidney function before starting NUCs may affect the potential nephrotoxicity caused by ETV and/or TDF. Consequently, renal safety is an important factor in choosing appropriate NUCs for the treatment of CHB because they are renally eliminated in an unchanged form, and this is particularly important in patients who have already had renal impairment or are at risk for it. 7, 14 The current review aimed to assess the potential renal toxicity associated with the use of ETV and TDF in patients infected with chronic HBV and to provide clinical perspectives on these two agents in the treatment of CHB.
Methods
A literature search was conducted to identify clinical studies in patients with HBV monoinfection, which assessed the safety of ETV and/or TDF. PubMed was searched from the inception of the database to March 2017, using "hepatitis B," "entecavir," and "tenofovir" as the search terms to find clinical trials written only in English. The reference lists of the selected articles and related reviews were utilized to find additional relevant articles. The data posted on ClinicalTrials.gov website were also used to identify the unpublished clinical outcomes. Two reviewers independently scanned the article titles and abstracts and identified relevant studies that met the following criteria: 1) retrospective or prospective clinical studies, 2) studies involving patients only with HBV infection, 3) studies in which ETV and/or TDF had to be administered for the treatment of HBV infection, and 4) studies whose results contained renal parameters, such as estimated glomerular filtration rate (eGFR), serum creatinine, and serum phosphorus, in order to evaluate the changes in renal function.
Results

Study characteristics
The literature search ( Figure 1 ) identified 21 eligible studies that met the predetermined inclusion criteria. The main characteristics of the selected studies are presented in Table 1 . 
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The final eligible studies included in this review were conducted in the United States, Europe, Thailand, Taiwan, Korea, and China. 3, [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] In particular, 13 studies were conducted on Asian individuals. [19] [20] [21] [22] [23] [25] [26] [27] [28] [29] [30] [31] 34 Most of the studies (61.9%), excluding five randomized clinical studies 19, 27, 29, 32, 34 and three studies that did not accurately report study designs, 24, 25, 28 were observational studies. Most studies were published in the last 2 years, although the articles dated back to 2011. Overall, 95.2% (20/21) of the studies were conducted on patients with mixed hepatitis B e antigen (HBeAg) status whereas only one study 33 did not report HBeAg status. The TDF dose used in the studies was 245 or 300 mg/day and that of ETV was 0.5 or 1 mg/day.
evaluation of renal safety of TDF and eTv
Information bias that may result from broad heterogeneity in the methodology among different studies was the major issue hindering meta-analyses. As presented in Table 2 , various parameters were utilized in order to measure renal functions after administering TDF and ETV. The most common parameter used was eGFR calculated using modification of diet in renal disease (MDRD) and CockcroftGault (CG) formulae.
An observational study comparing long-term renal functions reported eGFR in 424 patients with TDF-containing regimens and 187 patients with ETV according to the MDRD method. 15 In the patients with TDF-containing regimens, the mean eGFR decreased from 90.8 mL/min at BL to 85.1 mL/min at 60 months. However, in the patients with ETV, the mean eGFR increased from 81.2 mL/min at BL to 90.7 mL/min at 60 months. A retrospective-prospective cohort study conducted in Taiwan determined a change in eGFR in 37 patients with TDF and 62 patients with ETV based on the MDRD method. 20 In the patients with TDF, the mean eGFR changed from 78.3 mL/min/1.73 m 2 at BL to 73.0 mL/min/1.73 m 2 at 24 months, whereas in the patients with ETV, the mean eGFR increased from 75.6 mL/min/1.73 m 2 at BL to 79.3 mL/min/1.73 m 2 at 24 months. A similar change in eGFR calculated using the MDRD method was also observed in a retrospective cohort study conducted in Taiwan. 23 The mean eGFR in 170 patients with TDF changed from 92 mL/min/1.73 m 2 at BL to 86.3 mL/min/1.73 m 2 at 24 months; however, in 233 patients with ETV, the mean eGFR changed from 86.1 mL/min/1.73 m 2 at BL to 94.4 mL/min/1.73 m 2 at 24 months. A prospective cohort study conducted in Turkey reported a change in eGFR in 44 patients with TDF and 32 patients with ETV according to the Chronic Kidney Disease Epidemiology Collaboration and cystatin C (CKD-EPI-CysC) method. 16 The mean eGFR in the patients with TDF decreased from 84. 7 
Discussion
Close attention should be paid to the safety and efficacy of TDV and ETV for the long-term treatment of chronic HBV infection, because they are currently the most potent antiviral agents for treating HBV infection. 3, 5 TDF and ETV are likely to cause renal toxicity through various mechanisms including renal tubular injury, apoptosis, and mitochondrial toxicity. 5, 6 The present study reviewed the literature and provided a comprehensive summary of the renal safety of TDF and ETV for the treatment of patients with chronic HBV infection. The results based on the studies reviewed in this article indicated that TDF and ETV could be responsible at least for reduced kidney function in patients with chronic HBV infection.
In this study, the effects of TDF and ETV on renal function were assessed. Based on the markers of renal function, compared to patients treated with ETV, those treated with TDF were not more likely to show changes in renal function, although the eGFR of patients treated with TDF tended to be more clearly reduced than that of patients receiving ETV. The eGFRs of patients treated with TDF decreased in a time-dependent manner, whereas those of patients 
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Yang and Choi treated with ETV increased or decreased across various time points. 15, 16, 20, 23, 24, 28 Similar percentage of patients in both the treatment groups showed $20% decrease in eGFR during the treatment (based on CG, TDF 35.0% vs ETV 36.3%; based on MDRD, TDF 41.3% vs ETV 43.8%). 33 A similar tendency was also observed in a recent clinical trial conducted in Thailand. 19 After 36 months, 16.8% and 14.9% of patients receiving TDF and ETV, respectively, experienced $20% decrease in eGFR; however, the decrease was observed in more patients receiving TDF than in those receiving ETV at 12 and 24 months. 19 Around 30% of patients in both TDF and ETV groups experienced a $0.2 mg/dL increase in creatinine from BL; however, creatinine increase of $0.5 mg/dL from BL occurred in more patients receiving ETV than in those receiving TDF (13.8% vs 3.8%; p=0.025). 33 The frequencies of creatinine elevation by $0.3 mg/dL were similar in both groups (TDF/ETV 2.0% vs ETV 3.3%); however, creatinine elevation by $0.5 mg/dL was more frequent in patients treated with ETV alone (TDF/ETV 0.0% vs ETV 1.6%). 32 These heterogeneous results may be partially attributed to different characteristics, such as comorbidities and coadministered drugs, of the study subjects.
According to multivariate analyses, various risk factors, such as advanced age, preexisting renal failure, comorbidities, history of transplant, concomitant nephrotoxic drugs, advanced HIV coinfection, and male gender, were associated with eGFR reductions by TDF or ETV. 23, 26, 33, 35, 36 Especially, preexisting renal insufficiency was a major independent risk factor for deterioration of renal function during the treatment of chronic HBV infection. 23, 26, 33 Moreover, previous studies have reported an association of CHB with CKD, and ∼15%-30% of patients with CHB showed BL renal insufficiency or comorbidities that were likely to cause CKD, such as diabetes mellitus (DM) and HTN. [7] [8] [9] [10] [11] However, TDF therapy was not significantly associated with changes in renal function when compared with ETV therapy. 26, 33 Large proportions of TDF and ETV are also renally excreted in their unchanged forms. 37, 38 Thus, NUCs 
